EULAR
Refine Search
Biotechnology
Johnson & Johnson has announced that its drug nipocalimab demonstrated statistically significant and clinically meaningful improvements in a Phase II study for Sjögren’s disease (SjD). 18 June 2024
Biosimilars
Celltrion has announced positive Phase III data for CT-P47, a biosimilar referencing Actemra (tocilizumab). 14 June 2024
Biotechnology
Belgium’s UCB is sharing results from three studies supporting the value of Cimzia (certolizumab pegol) for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels. 13 June 2024
Biotechnology
One of the most important medical meetings in rheumatology is underway in Vienna, Austria, and leading drugmakers in the field have lifted the lid on data they intend to present. 12 June 2024
Biotechnology
Belgian biotech UCB has presented promising two-year data from Phase III studies on Bimzelx (bimekizumab) at the European Congress of Rheumatology, EULAR 2024. 12 June 2024
Biotechnology
Belgium’s largest drugmaker UCB will present new long-term 52-week data from three Phase III studies of bimekizumab at the 2023 meeting of the European Congress of Rheumatology (EULAR). 31 May 2023
Biosimilars
Korean biosimilar company Samsung Bioepis is presenting new data on its copy of Humira (adalimumab), which is branded as Imraldi and Hadlima and also referred to as SB5, at the Annual European Congress of Rheumatology (EULAR 2022). 1 June 2022
Biotechnology
At the annual European Congress of Rheumatology (EULAR 2022), presentations will include new data from two Phase III studies of bimekizumab, BE MOBILE 1 and BE MOBILE 2. 23 May 2022
Biotechnology
Russian pharma company R-Pharm has highlighted the views of four leading rheumatologists on its rheumatoid arthritis (RA) drug candidate olokizumab, which successfully completed international Phase III trials in 2020. 7 June 2021
Biotechnology
After a few disappointments in earlier clinical stages, a new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 2 June 2021
Biotechnology
Pharma giant Novartis has announced full positive results from the Phase III PREVENT trial of Cosentyx (secukinumab) in axial spondyloarthritis. 4 June 2020
Biotechnology
Interleukin (IL)-17A antagonist Taltz (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European Congress of Rheumatology 2020 (EULAR). 3 June 2020
Biotechnology
US pharma major Bristol-Myers Squibb today announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients who tested positive (seropositive) for certain autoantibodies. 3 June 2020
Biotechnology
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
Pharmaceutical
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid. 20 June 2019
Biotechnology
An oral presentation at the annual meeting of the European Congress of Rheumatology (EULAR) has detailed positive results from a Phase III study of brodalumab (KHK4827). 17 June 2019
Biosimilars
The Novartis division Sandoz has added to the case for European prescribers to switch rheumatoid arthritis (RA) patients taking AbbVie's Humira (adalimumab) to its biosimilar. 14 June 2019
Biotechnology
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
Biotechnology
Bimekizumab is a crucial pipeline drug for UCB – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker. 14 June 2019
Biotechnology
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Pharmaceutical
Mallinckrodt reported that all primary and secondary outcome measures were met in its Phase IV study of Acthar Gel (repository corticotropin injection) in persistently active rheumatoid arthritis (RA) patients previously treated with disease-modifying anti-rheumatic drugs and corticosteroids. 13 June 2019
Biotechnology
Convincing physicians that their drug is a better option than AbbVie’s Humira has been an aim of a lot of companies at the EULAR congress again this year – with the Chicago-based drugmaker among them. 13 June 2019
Biosimilars
The chance to persuade European rheumatologists and other healthcare practitioners to switch to or prescribe from the outset their anti-TNF biosimilars make EULAR a highly important event for Samsung Bioepis and Biogen (Nasdaq: BIIB). 12 June 2019
Biotechnology
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Pharmaceutical
German family-owned drugmaker Grünenthal has reported its findings from a pan-European survey on gout at the ongoing EULAR Congress. 12 June 2019
Biotechnology
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue. 7 June 2019
Pharmaceutical
Conference attendees gathered in the cavernous RAI Amsterdam convention center last week to hear the latest data from a therapy area valued at around $44 billion last year, and expected to reach over $50 billion by 2022. 22 June 2018
Biosimilars
There is more activity on the biosimilars front at the annual meeting of the European Congress of Rheumatology (EULAR), the leading conference in this therapy area, with positive preliminary data from South Korean firm Celltrion Healthcare. 15 June 2018
Biotechnology
Small molecule and biologic go head to head at the Annual European Congress of Rheumatology (EULAR) in Amsterdam on Friday morning, with oral presentations from Celgene and Janssen in psoriatic arthritis. 15 June 2018
Biosimilars
The USA-based generics arm of Novartis will present data from two long-term, Phase III studies of its biosimilar rheumatoid arthritis therapies at the Annual European Congress of Rheumatology (EULAR) today. 15 June 2018
Pharmaceutical
In an oral presentation to be given at the annual meeting of the European League Against Rheumatism (EULAR), US-based Celgene will present a post hoc analysis of data from the PALACE trial program that suggest new, previously uncaptured benefits of Otezla (apremilast) against psoriatic arthritis. 14 June 2018
Biotechnology
On Wednesday, the Annual European Congress of Rheumatology (EULAR) kicked off in Amsterdam, with a series of presentations to look forward to from rheumatic disease heavyweights AbbVie, Johnson & Johnson, Pfizer and others. 13 June 2018
Biotechnology
At the Annual European Congress of Rheumatology (EULAR), Chicago’s AbbVie presented new data from Phase III trials evaluating upadacitinib. 13 June 2018
Biosimilars
Under a coruscating Spanish sun, the 17th Annual European Congress of Rheumatology, EULAR, has at last drawn to a close in Madrid. 20 June 2017
Biosimilars
In an increasingly crowded anti-TNF market, Germany’s Boehringer Ingelheim believes that clinical data is key to differentiating its products and gaining market share. 20 June 2017
Biotechnology
On the penultimate day of the Annual European Congress of Rheumatology (EULAR), Britain's largest pharma company GlaxoSmithKline has provided data from a 10-year continuation study of Benlysta (belimumab). 16 June 2017
Biosimilars
Authorities in Denmark have put together a program designed to allay patient’s concerns over switching to biosimilars, in collaboration with the Danish Rheumatism Association. 16 June 2017
Biotechnology
With regulatory approval for a broader label pending in the USA, Eli Lilly as released more data on psoriatic arthritis candidate Taltz (ixekizumab) supporting the efficacy of the IL-17A inhibitor. 16 June 2017
Biotechnology
Eli Lilly and Incyte have announced new data from eight Olumiant clinical trials at EULAR, the Annual European Congress of Rheumatology, in Madrid. 16 June 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze